A prospective study analysing the Influence of the Multiple Sclerosis Modifying Drug Cladribine (2-Chlorodeoxyadenosine) Upon Primary Human Monocytes and Macrophages
Latest Information Update: 21 May 2020
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
Most Recent Events
- 21 May 2020 New trial record
- 01 May 2020 Results (N=10) assessing whether Cladribine modulates human macrophage polarization or monocyte differentiation, presented at the 72nd Annual Meeting of the American Academy of Neurology